Novo ended Akero deal talks before returning for $4.7B MASH acquisitionnews2025-10-27T07:40:11+00:00October 27th, 2025|Endpoints News|
Novartis to buy RNA drugmaker Avidity Biosciences for $12Bnews2025-10-26T17:46:26+00:00October 26th, 2025|Endpoints News|
Tracking pharma’s flights to DC; Novo’s boardroom drama; #ESMO25 recap from Berlin; and morenews2025-10-25T10:00:49+00:00October 25th, 2025|Endpoints News|
FDA approves Bayer’s hot flash treatmentnews2025-10-24T20:16:36+00:00October 24th, 2025|Endpoints News|
FDA uncovers unauthorized Indian API warehouse with lizards, catsnews2025-10-24T18:15:00+00:00October 24th, 2025|Endpoints News|
Halda reveals first clinical data of RIPTAC drug in prostate cancernews2025-10-24T18:13:58+00:00October 24th, 2025|Endpoints News|
Philly is on Lilly’s radar for next Gateway Labs sitenews2025-10-24T17:20:51+00:00October 24th, 2025|Endpoints News|
Lilly expands gene therapy work with Adverum acquisitionnews2025-10-24T15:09:02+00:00October 24th, 2025|Endpoints News|
FDA rejects Sydnexis’ myopia drug for kids; Chugai to buy Renalys for $98M upfrontnews2025-10-24T15:08:08+00:00October 24th, 2025|Endpoints News|
Biogen pays $70M upfront to Vanqua Bio for immunology drugnews2025-10-24T14:29:40+00:00October 24th, 2025|Endpoints News|
